Loading stock data…
Neurogene Inc. (NGNE)
$32.28+0.25 (+0.78%)
After Hours$32.28+0.00 (+0.00%)· Last close Jun 29
Neurogene Inc., a clinical stage biotechnology company, develops genetic medicines for rare neurological diseases.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Neurogene Inc. in the Healthcare sector is trading at $32.28 with a market capitalization of $414M. Wall Street consensus targets $80.00 (7 analysts), implying a +147.8% move over the next 12 months. The stock is currently 13% below its 52-week high of $37.27, remaining 37.4% above its 200-day moving average. On fundamentals, Piotroski 2/9 flags weak fundamentals, Altman Z in the safe zone. The Whystock Score of 90/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +147.8% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$33.35M↓ | -$27.53M↓ | -$23.80M↑ | -$26.08M↓ | -$25.92M |
| Net Income | -$30.93M↓ | -$24.73M↓ | -$20.95M↑ | -$22.02M↑ | -$22.65M |
Peer Comparison
JNJUNHPFE
Fundamentals
Neurogene Inc., a clinical stage biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 that is packaged in an adeno-associated virus 9, which is in Phase 1/2 clinical trial ...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$414.33M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
2.08
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-41.48%
Volume
Today's trading volume
543,393
Recent News
We Think Neurogene (NASDAQ:NGNE) Can Afford To Drive Business Growth
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Neurogene: Q4 Earnings Snapshot
On a per-share basis, the New York-based company said it had a loss of $1.12. The results surpassed Wall Street expectations. The average estimate of six analysts surveyed by Zacks Investment Research was for a loss of $1.20 per share.
Neurogene CEO Details NGN-401 Rett Trial, FDA Alignment, and Key 2026 Catalysts at Conference
Neurogene (NASDAQ:NGNE) CEO and founder Rachel McMinn outlined the company’s progress toward a potential commercial launch for its lead gene therapy candidate, NGN-401, during a fireside chat focused on Rett syndrome, regulatory alignment, trial design, and upcoming catalysts. Company focus and lea
Block upgraded, Duolingo downgraded: Wall Street's top analyst calls
Block upgraded, Duolingo downgraded: Wall Street's top analyst calls
Here Are Friday’s Top Wall Street Analyst Research Calls: Block, Costco, Dollar Tree, Duolingo, Palantir Technologies, Southwest Airlines, Synopsis, Warner Bros. Discovery, and More
Pre-Market Stock Futures: The futures are trading lower as we get set to conclude one of the zaniest trading weeks the stock market has seen in a long time. Despite crushing analysts’ earnings estimates and giving forward guidance above consensus, Nvidia Corp. (NASDAQ: NVDA) initially opened higher amid a rush of retail buying. Still, the ... Here Are Friday’s Top Wall Street Analyst Research Calls: Block, Costco, Dollar Tree, Duolingo, Palantir Technologies, Southwest Airlines, Synopsis, Warner